543245 Stock Overview
Engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Gland Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,644.85 |
| 52 Week High | ₹2,220.95 |
| 52 Week Low | ₹1,493.85 |
| Beta | 0.30 |
| 11 Month Change | -8.61% |
| 3 Month Change | -22.70% |
| 1 Year Change | 8.82% |
| 33 Year Change | -55.25% |
| 5 Year Change | n/a |
| Change since IPO | -9.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 543245 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.4% | 2.6% | 2.3% |
| 1Y | 8.8% | 59.1% | 37.9% |
Return vs Industry: 543245 underperformed the Indian Pharmaceuticals industry which returned 58.7% over the past year.
Return vs Market: 543245 underperformed the Indian Market which returned 37.7% over the past year.
Price Volatility
| 543245 volatility | |
|---|---|
| 543245 Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 543245 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 543245's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 4,208 | Srinivas Sadu | www.glandpharma.com |
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services.
Gland Pharma Limited Fundamentals Summary
| 543245 fundamental statistics | |
|---|---|
| Market cap | ₹271.24b |
| Earnings (TTM) | ₹7.22b |
| Revenue (TTM) | ₹58.58b |
37.6x
P/E Ratio4.6x
P/S RatioIs 543245 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 543245 income statement (TTM) | |
|---|---|
| Revenue | ₹58.58b |
| Cost of Revenue | ₹25.11b |
| Gross Profit | ₹33.47b |
| Other Expenses | ₹26.24b |
| Earnings | ₹7.22b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 04, 2024
| Earnings per share (EPS) | 43.83 |
| Gross Margin | 57.13% |
| Net Profit Margin | 12.33% |
| Debt/Equity Ratio | 4.3% |
How did 543245 perform over the long term?
See historical performance and comparison